PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a positive revenue increase and improved net loss, operating expenses, and gross margin, indicating operational improvements. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns, combined with negative cash flow and forward-looking risks, tempers enthusiasm. The absence of additional insights from the Q&A section further supports a neutral outlook. Without market cap data, the typical small-cap volatility cannot be considered.
Key Financial Performance
Revenue The company reported revenue of $5.2 million for Q1 2026, representing a 15% increase year-over-year, driven by higher sales volume and improved pricing strategies.
Net Loss Net loss for the quarter was $3.8 million, an improvement from the $4.5 million net loss in Q1 2025, attributed to cost-cutting measures and operational efficiencies.
Operating Expenses Operating expenses were $6.1 million, down 10% from $6.8 million in the same period last year, due to reduced R&D spending and administrative costs.
Gross Margin Gross margin improved to 62%, up from 58% in Q1 2025, reflecting better cost management and economies of scale.
Cash Flow Cash flow from operations was negative $2.5 million, compared to negative $3.2 million in the prior year, due to improved collections and reduced expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. These risks are detailed in the company's filings with the SEC, including the annual report on Form 10-K and quarterly reports on Form 10-Q.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aklog Chairman
Ascendiant Capital
CEO Dennis
CFO Edward
Capital Markets
Chairman CEO
Conference Instructions
Dennis McGrath
Division EDT
Division Jeremy
EDT PAVmed
Edward Woo
Group LLC
Instructions event
Jeremy Pearlman
LLC Research
Lishan Aklog
Markets LLC
McGrath President
PAVmed Vice
Pearlman Maxim
President CFO
President Investor
Relations Lishan
Research Division
Riley Senior
Vice President
Woo Ascendiant
conference PAVmed
event conference
PAVM Transcript
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call highlights a positive revenue increase and improved net loss, operating expenses, and gross margin, indicating operational improvements. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns, combined with negative cash flow and forward-looking risks, tempers enthusiasm. The absence of additional insights from the Q&A section further supports a neutral outlook. Without market cap data, the typical small-cap volatility cannot be considered.
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call summary presents a mixed outlook. While there are positive elements such as revenue growth in specialized loans and strategic partnerships, there are concerns about economic risks and funding reliance. The Q&A section reveals uncertainties around product timelines and management's vague responses, which may dampen investor confidence. The combination of positive and negative factors, along with the lack of market cap data, suggests a neutral stock price movement over the next two weeks.
Laurentian Bank of Canada (LB:CA) Q4 2025 Earnings Call Transcript
Unknown12-5
Basic Financial Performance shows mixed results with both positive and negative aspects. Product Development and Business Update lacks clarity, especially regarding the Fairstone transaction. Market Strategy and Expenses indicate a stable but cautious approach. Shareholder Return Plan is stable but restricted in dividend growth. Q&A reveals some concerns over branch closures and unclear future plans. Overall, the sentiment is neutral due to a balance of positive and negative factors, with no significant catalysts for a strong price movement.
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call summary indicates consistent revenue and financial metrics, but there are significant risks due to pending Medicare coverage and regulatory approvals. The Q&A session provided clarity on development timelines and strategies, but did not alleviate concerns about these risks. The equity investment loss and capital raise through a public offering add financial uncertainty. Overall, the sentiment is neutral due to the balance of consistent performance and ongoing risks.
PAVM Slides
PAVM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
